Key Details
Annual ROE
-288.67%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Mar 15, 2024Recent annual earnings:
Mar 15, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Oct 16, 2018Analyst ratings
Recent major analysts updates
22 Aug '23 Cantor Fitzgerald
Neutral03 Aug '23 William Blair
Market Perform03 Aug '23 HC Wainwright & Co.
Neutral03 Aug '23 EF Hutton
Hold03 Aug '23 BTIG
Neutral21 July '23 Cantor Fitzgerald
Overweight17 July '23 Cantor Fitzgerald
Overweight10 July '23 Cantor Fitzgerald
Overweight03 July '23 Cantor Fitzgerald
Overweight05 June '23 HC Wainwright & Co.
BuyScreeners with ARAV included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Aravive doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
Aravive (ARAV) Upgraded to Strong Buy: What Does It Mean for the Stock?
ARAV
Zacks Investment Research13 October 2023
Aravive (ARAV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Aravive (ARAV) Reports Q2 Loss, Tops Revenue Estimates
ARAV
Zacks Investment Research21 August 2023
Aravive (ARAV) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.61 per share a year ago.
Why Is Aravive (ARAV) Stock Down 58% Today?
ARAV
InvestorPlace03 August 2023
Aravive (NASDAQ: ARAV ) stock is plummeting on Thursday following the release of results from a Phase 3 clinical trial. The bad news hitting ARAV stock today is that its Phase 3 AXLerate-OC trial did not meet its primary endpoint.
What Makes Aravive (ARAV) a New Buy Stock
ARAV
Zacks Investment Research17 April 2023
Aravive (ARAV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
FAQ
- What is the primary business of Aravive?
- What is the ticker symbol for Aravive?
- Does Aravive pay dividends?
- What sector is Aravive in?
- What industry is Aravive in?
- What country is Aravive based in?
- When did Aravive go public?
- Is Aravive in the S&P 500?
- Is Aravive in the NASDAQ 100?
- Is Aravive in the Dow Jones?
- When was Aravive's last earnings report?
- When does Aravive report earnings?
- Should I buy Aravive stock now?
What is the primary business of Aravive?
Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.
What is the ticker symbol for Aravive?
The ticker symbol for Aravive is NASDAQ:ARAV
Does Aravive pay dividends?
No, Aravive does not pay dividends
What sector is Aravive in?
Aravive is in the Healthcare sector
What industry is Aravive in?
Aravive is in the Biotechnology industry
What country is Aravive based in?
Aravive is headquartered in United States
When did Aravive go public?
Aravive's initial public offering (IPO) was on 21 March 2014
Is Aravive in the S&P 500?
No, Aravive is not included in the S&P 500 index
Is Aravive in the NASDAQ 100?
No, Aravive is not included in the NASDAQ 100 index
Is Aravive in the Dow Jones?
No, Aravive is not included in the Dow Jones index
When was Aravive's last earnings report?
Aravive's most recent earnings report was on 15 March 2024
When does Aravive report earnings?
The date for Aravive's next earnings report has not been announced yet
Should I buy Aravive stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions